Lipocine vs Praxis Precision Medicines
LPCN and PRAX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LPCN and PRAX compare
Praxis Precision Medicines is the larger company, worth 633 times as much as Lipocine ($8.7B against $13.7M).
Lipocine scores higher on the StockData Score (9 against 7 for Praxis Precision Medicines), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LPCN | PRAX |
|---|---|---|
| Size and price | ||
| Market cap | $13.7M | $8.7B |
| Share price | $1.66 | $310.27 |
| Change, 1 year | −41.1% | 74.2% |
| Change, 5 years | −91.4% | 23.4% |
| Beta (5Y) | −0.43 | 1.90 |
| Employees | 14 | 168 |
| StockData Score | ||
| Total score | 9 (better) | 7 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 8.7× | – |
| P/B | 0.6× (better) | 6.5× |
| FCF yield | – | −3.5% |
| Fair value | $2.62 | – |
| Margin of safety | 36.5% | – |
| Growth | ||
| Revenue growth (TTM) | −62.7% | – |
| Profitability | ||
| Operating margin | −801% | – |
| Net margin | −755% | – |
| Return on equity | −60.9% | −38.9% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 11.48 | 15.73 (better) |
| Altman Z-score | −9.28 | 104.35 (better) |
| Piotroski F-score | 1 | 3 (better) |
| Dividends and buybacks | ||
| Buyback yield | −119% | – |
| Shareholder yield | −119% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 36.2% | 121% |
| Held by insiders | 9.0% | 0.72% |
| Insider net buying, 12 months | $596K (better) | −$3.6M |
| Short interest, % of float | 4.3% | 15.2% |
Go deeper
- LPCN stock overview
- LPCN income statement
- LPCN valuation and score
- PRAX stock overview
- PRAX income statement
- PRAX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.